SI1386917T1 - Intermediati za pripravo nekaterih triazolopirimidinov kot P2T antagonistov - Google Patents

Intermediati za pripravo nekaterih triazolopirimidinov kot P2T antagonistov

Info

Publication number: SI1386917T1
Authority: SI; Slovenia
Prior art keywords: antagonists; intermediates; preparation; triazolopyrimidines; certain
Prior art date: 1998-12-04

Application number

SI9931059T

Other languages

English (en)

Inventor

David Hardern

Anthony Ingall

Brian Springthorpe

Paul Willis

Simon Guile

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-04

Filing date

1999-12-02

Publication date

2011-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1386917(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-12-04 Priority claimed from SE9804211A external-priority patent/SE9804211D0/xx

1999-04-09 Priority claimed from SE9901271A external-priority patent/SE9901271D0/xx

1999-12-02 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2011-09-30 Publication of SI1386917T1 publication Critical patent/SI1386917T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

SI9931059T 1998-12-04 1999-12-02 Intermediati za pripravo nekaterih triazolopirimidinov kot P2T antagonistov SI1386917T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SE9804211A SE9804211D0 (sv)	1998-12-04	1998-12-04	Novel compounds
SE9901271A SE9901271D0 (sv)	1999-04-09	1999-04-09	Novel compounds
EP03025535A EP1386917B1 (en)	1998-12-04	1999-12-02	Intermediates for the preparation of certain triazolopyrimidines as P2T antagonists

Publications (1)

Publication Number	Publication Date
SI1386917T1 true SI1386917T1 (sl)	2011-09-30

Family

ID=26663448

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SI9930550T SI1135391T1 (sl)	1998-12-04	1999-12-02	Nove triazolo(4,5-D)pirimidinske spojine
SI9931059T SI1386917T1 (sl)	1998-12-04	1999-12-02	Intermediati za pripravo nekaterih triazolopirimidinov kot P2T antagonistov
SI9931026T SI1386921T1 (sl)	1998-12-04	1999-12-02	Intermediati za pripravo antitrombotičnih 4H-ciklopenta-1,3-dioksolnih derivatov

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SI9930550T SI1135391T1 (sl)	1998-12-04	1999-12-02	Nove triazolo(4,5-D)pirimidinske spojine

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI9931026T SI1386921T1 (sl)	1998-12-04	1999-12-02	Intermediati za pripravo antitrombotičnih 4H-ciklopenta-1,3-dioksolnih derivatov

Country Status (36)

Country	Link
US (12)	USRE46276E1 (sl)
EP (5)	EP1135391B1 (sl)
JP (4)	JP4202607B2 (sl)
KR (4)	KR100742924B1 (sl)
CN (1)	CN1128801C (sl)
AR (3)	AR023920A1 (sl)
AT (3)	ATE418547T1 (sl)
AU (1)	AU766618B2 (sl)
BR (1)	BRPI9915883B8 (sl)
CA (1)	CA2351709C (sl)
CY (3)	CY1110501T1 (sl)
CZ (3)	CZ300280B6 (sl)
DE (4)	DE69940171D1 (sl)
DK (3)	DK1386921T3 (sl)
EG (1)	EG24814A (sl)
ES (3)	ES2216623T3 (sl)
FR (1)	FR11C0016I2 (sl)
HK (1)	HK1039933B (sl)
HU (2)	HU228589B1 (sl)
ID (1)	ID29927A (sl)
IL (6)	IL143232A0 (sl)
LT (1)	LTPA2011004I1 (sl)
LU (1)	LU91819I2 (sl)
MY (1)	MY121867A (sl)
NO (3)	NO319806B1 (sl)
NZ (1)	NZ511778A (sl)
PL (1)	PL201283B1 (sl)
PT (2)	PT1135391E (sl)
RU (3)	RU2317990C2 (sl)
SA (1)	SA99200848B1 (sl)
SI (3)	SI1135391T1 (sl)
SK (1)	SK286007B6 (sl)
TR (1)	TR200101567T2 (sl)
TW (1)	TWI229674B (sl)
WO (1)	WO2000034283A1 (sl)
ZA (1)	ZA200104094B (sl)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI229674B (en)	1998-12-04	2005-03-21	Astra Pharma Prod	Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9903290D0 (sv) *	1999-09-15	1999-09-15	Astra Pharma Prod	Novel compounds
SE9904129D0 (sv)	1999-11-15	1999-11-15	Astra Pharma Prod	Novel compounds
SE9904377D0 (sv) *	1999-12-01	1999-12-01	Astra Pharma Prod	Pharmaceutical combinations
TWI290549B (en) *	2000-06-02	2007-12-01	Astrazeneca Ab	Process for the preparation of cyclopropyl carboxylic acid ester and derivatives
GB0013407D0 (en) *	2000-06-02	2000-07-26	Astrazeneca Ab	Forms of a chemical compound
GB0013488D0 (en) *	2000-06-02	2000-07-26	Astrazeneca Ab	Chemical compound
US7018985B1 (en)	2000-08-21	2006-03-28	Inspire Pharmaceuticals, Inc.	Composition and method for inhibiting platelet aggregation
US6897201B2 (en)	2000-08-21	2005-05-24	Inspire Pharmaceuticals, Inc.	Compositions and methods for the treatment of glaucoma or ocular hypertension
US7115585B2 (en)	2000-08-21	2006-10-03	Inspire Pharmaceuticals, Inc.	Compositions for treating epithelial and retinal tissue diseases
US7452870B2 (en)	2000-08-21	2008-11-18	Inspire Pharmaceuticals, Inc.	Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7132408B2 (en)	2000-08-21	2006-11-07	Inspire Pharmaceuticals, Inc.	Composition and method for inhibiting platelet aggregation
SE0101932D0 (sv) *	2001-05-31	2001-05-31	Astrazeneca Ab	Pharmaceutical combinations
US7435724B2 (en)	2002-02-27	2008-10-14	Inspire Pharmaceutical, Inc.	Degradation-resistant mononucleoside phosphate compounds
US7488739B2 (en)	2003-07-24	2009-02-10	Astellas Pharma Inc.	Quinolone derivative or salt thereof
SE0401001D0 (sv)	2004-03-31	2004-03-31	Astrazeneca Ab	Chemical process
SE0400873D0 (sv) *	2004-03-31	2004-03-31	Astrazeneca Ab	Chemical process
EP1598354A1 (en) *	2004-05-18	2005-11-23	Vasopharm Biotech GmbH	Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation
WO2007020935A1 (ja) *	2005-08-17	2007-02-22	Ono Pharmaceutical Co., Ltd.	Ｐ２ｙ１２受容体および／またはｐ２ｙ１４受容体ブロッカーを含有してなる疼痛治療剤
TWI391378B (zh)	2006-03-16	2013-04-01	Astellas Pharma Inc	喹啉酮衍生物或其製藥學上可被容許之鹽
GB0615620D0 (en)	2006-08-05	2006-09-13	Astrazeneca Ab	A process for the preparation of optically active intermediates
US20080045548A1 (en) *	2006-08-21	2008-02-21	Astrazeneca Ab	Pharmaceutical Compositions
TWI482772B (zh) *	2006-08-21	2015-05-01	Astrazeneca Ab	適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2008054795A2 (en) *	2006-10-31	2008-05-08	Janssen Pharmaceutica, N.V.	Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
TWI496776B (zh) *	2007-11-15	2015-08-21	Astrazeneca Ab	製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
UA100864C2 (uk) *	2007-12-03	2013-02-11	Астразенека Аб	Спосіб лікування або запобігання аневризмі черевної аорти
TWI389913B (zh) *	2008-09-08	2013-03-21	Lg Life Sciences Ltd	并合雜環化合物
RU2509082C2 (ru) *	2008-09-09	2014-03-10	Астразенека Аб	СПОСОБ ПОЛУЧЕНИЯ [1S-[1α,2α,3β(1S,2R),5β]]-3-[7-[2-(3,4-ДИФТОРФЕНИЛ)-ЦИКЛОПРОПИЛАМИНО]-5-(ПРОПИЛТИО)-3H-1,2,3-ТРИАЗОЛО[4,5-d]ПИРИМИДИН-3-ИЛ]-5-(2-ГИДРОКСИЭТОКСИ)-ЦИКЛОПЕНТАН-1,2-ДИОЛА И ЕГО ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ
WO2010043721A1 (en)	2008-10-17	2010-04-22	Oryzon Genomics, S.A.	Oxidase inhibitors and their use
EP2389362B1 (en)	2009-01-21	2019-12-11	Oryzon Genomics, S.A.	Phenylcyclopropylamine derivatives and their medical use
EP3135675A1 (en)	2009-07-27	2017-03-01	Auspex Pharmaceuticals, Inc.	Deuterated derivatives of ticagrelor for medical use
EP2305376A1 (en)	2009-09-23	2011-04-06	Lonza Ltd.	Process and catalyst for the catalytic hydrogenation of aromatic and heteroaromatic nitro compounds
BR112012006572A2 (pt)	2009-09-25	2016-04-26	Oryzon Genomics Sa	inibidores de demetilase-1 de lisina específicos e seu uso
EP2486002B1 (en)	2009-10-09	2019-03-27	Oryzon Genomics, S.A.	Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
JP2013512886A (ja)	2009-12-03	2013-04-18	アストラゼネカアクチボラグ	血小板の凝集阻害剤トリアゾロ［４，５−ｄ］ピリミジン共結晶
US8663661B2 (en)	2009-12-23	2014-03-04	Ratiopharm Gmbh	Solid pharmaceutical dosage form of ticagrelor
AU2011216991A1 (en)	2010-02-16	2012-08-30	Actavis Group Ptc Ehf	Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
US9616058B2 (en)	2010-02-24	2017-04-11	Oryzon Genomics, S.A.	Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
WO2011106106A2 (en)	2010-02-24	2011-09-01	Oryzon Genomics, S.A.	Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
JP5868948B2 (ja)	2010-04-19	2016-02-24	オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎＧｅｎｏｍｉｃｓＳ．Ａ．	リジン特異的脱メチル化酵素１阻害薬およびその使用
EP2560939A2 (en)	2010-04-20	2013-02-27	Actavis Group Ptc Ehf	Novel process for preparing phenylcyclopropylamine derivatives using novel intermediates
US20130165696A1 (en)	2010-06-30	2013-06-27	Actavis Group Ptc Ehf	Novel processes for the preparation of phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor
US9006449B2 (en)	2010-07-29	2015-04-14	Oryzon Genomics, S.A.	Cyclopropylamine derivatives useful as LSD1 inhibitors
ES2674747T3 (es)	2010-07-29	2018-07-03	Oryzon Genomics, S.A.	Inhibidores de demetilasa LSD1 basados en arilciclopropilamina y sus usos médicos
WO2012045883A1 (en)	2010-10-08	2012-04-12	Oryzon Genomics S.A.	Cyclopropylamine inhibitors of oxidases
WO2012063126A2 (en)	2010-11-09	2012-05-18	Actavis Group Ptc Ehf	Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material
WO2012072713A2 (en)	2010-11-30	2012-06-07	Oryzon Genomics, S.A.	Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2655341A2 (en) *	2010-12-20	2013-10-30	Actavis Group Ptc Ehf	Novel processes for preparing triazolo[4,5-d]pyrimidine derivatives and intermediates thereof
EP3981395A1 (en)	2011-02-08	2022-04-13	Oryzon Genomics, S.A.	Lysine demethylase inhibitors for myeloproliferative disorders
CN102653539B (zh) *	2011-03-01	2014-09-17	秦引林	一种抗血小板聚集化合物及其药物组合
WO2012138981A2 (en)	2011-04-06	2012-10-11	Teva Pharmaceutical Industries Ltd.	New intermediates and processes for preparing ticagrelor
CN102731510B (zh) *	2011-04-07	2015-12-16	博瑞生物医药（苏州）股份有限公司	替卡格雷的衍生物、制备方法及其药物用途
CZ2011229A3 (cs) *	2011-04-19	2012-08-15	Zentiva, K.S.	Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy
CA2834935A1 (en) *	2011-05-13	2012-11-22	Astrazeneca Ab	A process for the preparation of benzyl [(3as,4r,6s,6ar)-6-hydroxy-2,2-dimethyltetrahydro-3ah-cyclopenta[d][1,3]dioxol]-4-yl]carbamate and intermediates in the process
US20140296255A1 (en) *	2011-05-19	2014-10-02	Oryzong Genomics, S.A.	Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
US20140329833A1 (en) *	2011-05-19	2014-11-06	Oryzon Genomics, S.A	Lysine demethylase inhibitors for inflammatory diseases or conditions
RU2013154741A (ru)	2011-06-01	2015-07-20	Астразенека Аб	Новый сокристалл тикагрелора
US20140206867A1 (en)	2011-06-15	2014-07-24	Actavis Group Ptc Ehf	Process for Preparing Cyclopentylamine Derivatives and Intermediates Thereof
CN102924457A (zh) *	2011-08-12	2013-02-13	上海恒瑞医药有限公司	三唑并嘧啶类衍生物、其制备方法及其用途
EP2570405A1 (en)	2011-09-14	2013-03-20	LEK Pharmaceuticals d.d.	Synthesis of Triazolopyrimidine Compounds
PL2755957T4 (pl)	2011-09-14	2017-05-31	Lek Pharmaceuticals D.D.	Synteza związków triazolopirymidynowych
EP2768805B1 (en)	2011-10-20	2020-03-25	Oryzon Genomics, S.A.	(hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
RU2668952C2 (ru)	2011-10-20	2018-10-05	Оризон Дженомикс, С.А.	(гетеро)арилциклопропиламины в качестве ингибиторов lsd1
CA2852652A1 (en)	2011-10-27	2013-05-02	Lek Pharmaceuticals D.D.	Synthesis of triazolopyrimidine compounds
EP2586773A1 (en)	2011-10-27	2013-05-01	LEK Pharmaceuticals d.d.	Synthesis of Triazolopyrimidine Compounds
EP2589587A1 (en)	2011-11-04	2013-05-08	Chemo Ibérica, S.A.	Synthesis of nitrogen substituted cyclopropanes
WO2013079589A1 (en)	2011-11-30	2013-06-06	Actavis Group Ptc Ehf	Novel crystalline form of ticagrelor and process for the preparation thereof
WO2013092900A1 (en)	2011-12-23	2013-06-27	Lek Pharmaceuticals D.D.	Synthesis of triazolopyrimidine compounds
EP2607355A1 (en) *	2011-12-23	2013-06-26	LEK Pharmaceuticals d.d.	Synthesis of triazolopyrimidine compounds
EP2628721A1 (en)	2012-02-20	2013-08-21	LEK Pharmaceuticals d.d.	Synthesis of 2-(3,4-difluorophenyl)cyclopropanecarboxylic acid
WO2013144295A1 (en)	2012-03-30	2013-10-03	Sandoz Ag	Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts
EP2644590A1 (en)	2012-03-30	2013-10-02	LEK Pharmaceuticals d.d.	Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts
US9233966B2 (en)	2012-04-05	2016-01-12	Dr. Reddy's Laboratories Limited	Preparation of ticagrelor
WO2013163892A1 (en) *	2012-05-02	2013-11-07	Sunshine Lake Pharma Co., Ltd.	Novel triazolo pyrimidine compounds and a process of preparation thereof
CN102659815B (zh) *	2012-05-04	2013-07-17	开原亨泰制药股份有限公司	一种制备选择性抗凝血药替卡格雷及其中间体的方法
EP2666771A1 (en)	2012-05-24	2013-11-27	LEK Pharmaceuticals d.d.	Synthesis of Aminocyclopentanetriol Derivatives
ITMI20121142A1 (it) *	2012-06-28	2013-12-29	Chemo Iberica Sa	Processo chemoenzimatico per la produzione di fenil ciclopropilammine
WO2014000719A1 (en)	2012-06-29	2014-01-03	Zentiva, K.S.	Novel pharmaceutical solid forms of (1s,2s,3r,5s)-3-[7-[(1r,2s)-2-(3,4difluorophenyl)cyclopropylamino]-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol
WO2014006091A1 (en)	2012-07-04	2014-01-09	Lek Pharmaceuticals D.D.	Ticagrelor adducts with divalent metal salts
CN103626743B (zh) *	2012-08-23	2018-06-08	广东东阳光药业有限公司	替卡格雷的新型中间体及其制备方法
CN102875537A (zh) *	2012-09-10	2013-01-16	常州制药厂有限公司	一种新的抗血栓药物的制备方法
CZ2012705A3 (cs)	2012-10-16	2014-04-23	Zentiva, K.S.	Pevná orální farmaceutická formulace obsahující ticagrelor
WO2014083139A1 (en)	2012-11-29	2014-06-05	Actavis Group Ptc Ehf	Novel amorphous form of ticagrelor
WO2014102830A1 (en)	2012-12-31	2014-07-03	Megafine Pharma (P) Ltd.	A process for preparation of ticagrelor and intermediates thereof
CN104045620B (zh) *	2013-03-12	2017-05-10	博瑞生物医药（苏州）股份有限公司	一种替卡格雷中间体的制备方法
CZ307217B6 (cs)	2013-03-14	2018-04-04	Zentiva, K.S.	Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
IN2013MU01111A (sl) *	2013-03-25	2015-05-01	Glenmark Generics Ltd
ITMI20130487A1 (it)	2013-03-29	2014-09-30	Chemo Res S L	Alchilazione selettiva di ciclopentilalcoli
CN104098553B (zh)	2013-04-10	2017-11-28	江苏恒瑞医药股份有限公司	替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
EP2813216A1 (en)	2013-06-10	2014-12-17	Zentiva, a.s.	Stabilized amorphous ticagrelor
WO2014170026A1 (en)	2013-04-18	2014-10-23	Zentiva, K.S.	Stabilized amorphous ticagrelor
CN104230818B (zh) *	2013-06-06	2018-01-12	郝聪梅	替卡格雷中间体的改进制备方法
EP2816043A1 (en)	2013-06-21	2014-12-24	LEK Pharmaceuticals d.d.	Spherical ticagrelor particles
WO2014206187A1 (zh)	2013-06-24	2014-12-31	苏州明锐医药科技有限公司	替卡格雷及其中间体的制备方法
CN104250251B (zh) *	2013-06-25	2017-05-17	上海京新生物医药有限公司	一种替格瑞洛的制备方法
WO2015001489A1 (en)	2013-07-01	2015-01-08	Ranbaxy Laboratories Limited	Pharmaceutical compositions of ticagrelor
CZ2013866A3 (cs)	2013-11-08	2015-05-20	Zentiva, K.S.	Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
WO2015110952A1 (en)	2014-01-21	2015-07-30	Wockhardt Limited	Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN103992323B (zh) *	2014-04-18	2017-03-29	南通常佑药业科技有限公司	一种替格瑞洛的制备方法
WO2015162630A1 (en)	2014-04-25	2015-10-29	Anlon Chemical Research Organization	Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
DE102014108210A1 (de)	2014-06-11	2015-12-17	Dietrich Gulba	Rodentizid
US10011605B2 (en)	2014-06-18	2018-07-03	Flamma Spa	Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds
CN105272985B (zh) *	2014-06-24	2017-11-21	珠海联邦制药股份有限公司	三唑并[4,5‑d]嘧啶化合物及其合成方法、用途、组合物
WO2016001851A1 (en) *	2014-07-02	2016-01-07	Dr. Reddy's Laboratories Limited	Preparation of ticagrelor
CN106715473B (zh)	2014-10-01	2021-11-23	免疫医疗有限公司	替格瑞洛的抗体及其使用方法
WO2016116942A1 (en)	2015-01-20	2016-07-28	Anlon Chemical Research Organization	Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN105985346B (zh) *	2015-03-06	2019-10-18	苏州朗科生物技术股份有限公司	一种新的替格瑞洛化合物制备方法及其中间体化合物
US9789087B2 (en)	2015-08-03	2017-10-17	Thomas Jefferson University	PAR4 inhibitor therapy for patients with PAR4 polymorphism
CN105237540B (zh) *	2015-09-21	2017-10-03	南京正大天晴制药有限公司	一种替格瑞洛有关物质的制备方法、检测方法及用途
WO2017118633A1 (en)	2016-01-05	2017-07-13	Amneal Pharmaceuticals Company Gmbh	Crystalline form of ticagrelor
TR201601835A2 (tr)	2016-02-12	2017-08-21	Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi	Ti̇kagrelor i̇çeren formülasyonlar i̇çi̇n üreti̇m yöntemi̇
US20170296666A1 (en)	2016-04-18	2017-10-19	Amneal Pharmaceuticals Company Gmbh	Stable Pharmaceutical Composition Of Amorphous Ticagrelor
CN107595789B (zh)	2016-04-21	2021-01-15	阿斯利康(瑞典)有限公司	口腔崩解片
KR20190040054A (ko) *	2016-08-26	2019-04-16	미쓰비시 타나베 파마 코퍼레이션	이환식 함질소 헤테로환 화합물
ES2731658T3 (es)	2016-09-09	2019-11-18	Univ Liege	Derivados triazolo(4,5-d)pirimidina para uso en la prevención y tratamiento de infección bacteriana
US10905691B2 (en)	2016-09-09	2021-02-02	Université de Liège	Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
CN107814772A (zh) *	2017-11-24	2018-03-20	常州沃腾化工科技有限公司	4,6‑二氯‑5‑氨基‑2‑丙硫基嘧啶酯的精制方法
EP3527571A1 (en) *	2018-02-14	2019-08-21	Université de Liège	Pyrimidine derivatives for prevention and treatment of bacterial infection
WO2020021110A1 (en)	2018-07-27	2020-01-30	Krka, D.D., Novo Mesto	Pharmaceutical composition of ticagrelor
CN109761785A (zh) *	2019-02-16	2019-05-17	安徽诺全药业有限公司	一种(1r，2r）-2-(3,4-二氟苯基)环丙烷羧酸的合成方法
GB201910656D0 (en)	2019-07-25	2019-09-11	Univ Liege	New use of triazolo(4,5-d)Pyrimidine deerivatives
EP3919497A1 (en)	2020-06-04	2021-12-08	Zaklady Farmaceutyczne Polpharma S.A.	Process for the preparation of ticagrelor
CN112876485A (zh) *	2021-01-25	2021-06-01	郭丽伟	一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
EP4070658A1 (de)	2021-04-06	2022-10-12	BIORoxx GmbH	Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
CN117003756A (zh) *	2022-05-04	2023-11-07	华东师范大学	芳香稠环化合物作为trek-1激活剂的用途、包含其的药物组合物、镇痛剂
CN119080782A (zh) *	2024-10-10	2024-12-06	重庆普佑生物医药有限公司	替卡格雷的合成方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3106578A (en)	1960-09-16	1963-10-08	Smith Kline French Lab	Nu-phenethyl-2-phenylcyclopropylamine derivatives
SE329623B (sl)	1967-06-08	1970-10-19	C F Boehringer Soehne Gmbh
DE1670265A1 (de)	1967-08-25	1971-01-28	Boehringer Mannheim Gmbh	2-Amino-Adenosinderivate und Verfahren zu deren Herstellung
CH558137A (de)	1971-05-17	1975-01-31	Ciba Geigy Ag	Mittel zur beeinflussung des pflanzenwachstums.
US4016204A (en)	1975-10-31	1977-04-05	Nelson Research & Development Company	Method of synthesis of trans-2-phenylcyclopropylamine
US4543255A (en)	1984-05-10	1985-09-24	Southern Research Institute	Carbocyclic analogs of purine 2'-deoxyribofuranosides
US4742064A (en)	1985-09-10	1988-05-03	Regents Of The University Of Minnesota	Antiviral carbocyclic analogs of xylofuranosylpurines
FI93546C (fi)	1988-01-20	1995-04-25	Univ Minnesota	Menetelmä terapeuttisesti käyttökelpoisten dideoksikarbosyklisten nukleosidianalogien valmistamiseksi
KR910700054A (ko)	1988-12-12	1991-03-13	엠. 팔레스 피터	B형 간염 비루스 감염의 예방 및 치료를 위한 방법 및 조성물
US5110933A (en)	1989-11-13	1992-05-05	Board Of Regents Of Oklahoma State University	Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof
US5652366A (en)	1990-09-25	1997-07-29	Rhone-Poulenc Rorer Pharmaceuticals Inc.	DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
WO1992012718A1 (en)	1991-01-23	1992-08-06	Gensia, Inc.	Adenosine kinase inhibitors
PL297372A1 (en)	1991-04-06	1993-09-06	Fisons Plc	Atp analogs
EP0521463A3 (en)	1991-07-04	1993-04-14	Hoechst Aktiengesellschaft	Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents
FI101150B (fi)	1991-09-09	1998-04-30	Sankyo Co	Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US5817660A (en)	1991-12-06	1998-10-06	Hoechst Marion Roussel, Inc.	Trans cyclopentanyl purine analogs useful as immunosuppressants
TW224044B (sl) *	1991-12-30	1994-05-21	Shell Internat Res Schappej B V
US5338725A (en)	1992-06-30	1994-08-16	The Research Foundation Of The State University Of New York	Anti-aggregatory agents for platelets
IL108523A0 (en)	1993-02-03	1994-05-30	Gensia Inc	Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
ES2108425T3 (es)	1993-02-10	1997-12-16	Astra Pharma Prod	Analogos de atp sustituidos con n-alquilo-2.
US5688774A (en)	1993-07-13	1997-11-18	The United States Of America As Represented By The Department Of Health And Human Services	A3 adenosine receptor agonists
US5620676A (en)	1994-03-08	1997-04-15	The United States Of America As Represented By The Department Of Health And Human Services	Biologically active ATP analogs
US5831099A (en)	1995-03-10	1998-11-03	The United States Of America As Represented By The Secretary Of The Army	Compounds of 1,5-disubstituted-3,7 diaza bicyclo 3.3.0! octanes and products containing the same
US5712258A (en)	1995-03-23	1998-01-27	The Trustees Of The University Of Pennsylvania	Inotropic ADP and ATP analogues and their pharmaceutical compositions
US6143749A (en)	1995-06-07	2000-11-07	Abbott Laboratories	Heterocyclic substituted cyclopentane compounds
KR100444123B1 (ko)	1995-07-11	2004-10-14	아스트라제네카 악티에볼라그	신규한혈소판응집억제제
EP0864572B1 (en)	1995-09-01	2001-04-25	Hokuriku Seiyaku Co., Ltd.	Crystal of hydrate and process for preparation thereof
EP0862628B1 (en)	1995-11-21	2004-06-30	Euroscreen S.A.	Receptor and nucleic acid molecule encoding said receptor
US5948437A (en)	1996-05-23	1999-09-07	Zeneca Limited	Pharmaceutical compositions using thiazepine
DE69710490T2 (de) *	1996-12-20	2002-10-24	Astrazeneca Ab, Soedertaelje	Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
JPH10258654A (ja)	1997-03-18	1998-09-29	Delta Tsuuring:Kk	リクライニングシート
SE9702772D0 (sv)	1997-07-22	1997-07-22	Astra Pharma Prod	Novel compounds
TW530058B (en)	1997-07-22	2003-05-01	Astra Pharma Prod	Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation
SE9702773D0 (sv)	1997-07-22	1997-07-22	Astra Pharma Prod	Novel compounds
SE9702775D0 (sv)	1997-07-22	1997-07-22	Astra Pharma Prod	Novel compounds
SE9704709D0 (sv)	1997-12-17	1997-12-17	Astra Ab	Pharmaceutically active compounds
TWI229674B (en)	1998-12-04	2005-03-21	Astra Pharma Prod	Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
DE60020010T2 (de)	1999-06-21	2006-01-19	Yamamoto Chemicals, Inc., Yao	Polymethinverbindungen, Verfahren zu deren Herstellung und deren Verwendung
SE9903759D0 (sv)	1999-10-18	1999-10-18	Astra Ab	Pharmaceutically active compounds
CN1187354C (zh)	1999-11-12	2005-02-02	拜奥根有限公司	腺苷受体拮抗剂以及制造和使用它们的方法
GB0013407D0 (en)	2000-06-02	2000-07-26	Astrazeneca Ab	Forms of a chemical compound
US7040429B2 (en)	2001-10-10	2006-05-09	Invacare Corporation	Wheelchair suspension
EP1455758A1 (en)	2001-12-21	2004-09-15	Pfizer Products Inc.	Directly compressible formulations of azithromycin
TWI482772B (zh)	2006-08-21	2015-05-01	Astrazeneca Ab	適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
RU2509082C2 (ru)	2008-09-09	2014-03-10	Астразенека Аб	СПОСОБ ПОЛУЧЕНИЯ [1S-[1α,2α,3β(1S,2R),5β]]-3-[7-[2-(3,4-ДИФТОРФЕНИЛ)-ЦИКЛОПРОПИЛАМИНО]-5-(ПРОПИЛТИО)-3H-1,2,3-ТРИАЗОЛО[4,5-d]ПИРИМИДИН-3-ИЛ]-5-(2-ГИДРОКСИЭТОКСИ)-ЦИКЛОПЕНТАН-1,2-ДИОЛА И ЕГО ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ
AU2011216991A1 (en)	2010-02-16	2012-08-30	Actavis Group Ptc Ehf	Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
US20130165696A1 (en)	2010-06-30	2013-06-27	Actavis Group Ptc Ehf	Novel processes for the preparation of phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor
EP2655341A2 (en)	2010-12-20	2013-10-30	Actavis Group Ptc Ehf	Novel processes for preparing triazolo[4,5-d]pyrimidine derivatives and intermediates thereof
WO2012138981A2 (en)	2011-04-06	2012-10-11	Teva Pharmaceutical Industries Ltd.	New intermediates and processes for preparing ticagrelor
US20140206867A1 (en)	2011-06-15	2014-07-24	Actavis Group Ptc Ehf	Process for Preparing Cyclopentylamine Derivatives and Intermediates Thereof
WO2013079589A1 (en)	2011-11-30	2013-06-06	Actavis Group Ptc Ehf	Novel crystalline form of ticagrelor and process for the preparation thereof
US9233966B2 (en)	2012-04-05	2016-01-12	Dr. Reddy's Laboratories Limited	Preparation of ticagrelor
WO2014083139A1 (en)	2012-11-29	2014-06-05	Actavis Group Ptc Ehf	Novel amorphous form of ticagrelor
WO2014102830A1 (en)	2012-12-31	2014-07-03	Megafine Pharma (P) Ltd.	A process for preparation of ticagrelor and intermediates thereof
WO2014118808A2 (en)	2013-02-04	2014-08-07	Hetero Research Foundation	Ticagrelor solid dispersion
CN104098553B (zh)	2013-04-10	2017-11-28	江苏恒瑞医药股份有限公司	替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
WO2014195861A2 (en)	2013-06-04	2014-12-11	Dr. Reddy’S Laboratories Limited	Preparation of ticagrelor
WO2016001851A1 (en)	2014-07-02	2016-01-07	Dr. Reddy's Laboratories Limited	Preparation of ticagrelor
AU2016210973B2 (en)	2015-01-27	2019-02-14	Astrazeneca Ab	Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction

1999
- 1999-11-19 TW TW088120241A patent/TWI229674B/zh not_active IP Right Cessation
- 1999-12-02 ES ES99963796T patent/ES2216623T3/es not_active Expired - Lifetime
- 1999-12-02 PT PT99963796T patent/PT1135391E/pt unknown
- 1999-12-02 WO PCT/SE1999/002256 patent/WO2000034283A1/en not_active Ceased
- 1999-12-02 DK DK03025536T patent/DK1386921T3/da active
- 1999-12-02 HU HU0105081A patent/HU228589B1/hu active Protection Beyond IP Right Term
- 1999-12-02 SI SI9930550T patent/SI1135391T1/sl unknown
- 1999-12-02 SI SI9931059T patent/SI1386917T1/sl unknown
- 1999-12-02 BR BRPI9915883A patent/BRPI9915883B8/pt not_active IP Right Cessation
- 1999-12-02 AU AU20165/00A patent/AU766618B2/en not_active Expired
- 1999-12-02 CZ CZ20041089A patent/CZ300280B6/cs not_active IP Right Cessation
- 1999-12-02 MY MYPI99005232A patent/MY121867A/en unknown
- 1999-12-02 PL PL348724A patent/PL201283B1/pl unknown
- 1999-12-02 RU RU2001118284/04A patent/RU2317990C2/ru active Protection Beyond IP Right Term
- 1999-12-02 CZ CZ20080600A patent/CZ300373B6/cs not_active IP Right Cessation
- 1999-12-02 EP EP99963796A patent/EP1135391B1/en not_active Expired - Lifetime
- 1999-12-02 DE DE69940171T patent/DE69940171D1/de not_active Expired - Lifetime
- 1999-12-02 NZ NZ511778A patent/NZ511778A/en not_active IP Right Cessation
- 1999-12-02 SK SK749-2001A patent/SK286007B6/sk not_active IP Right Cessation
- 1999-12-02 JP JP2000586728A patent/JP4202607B2/ja not_active Expired - Lifetime
- 1999-12-02 CN CN99815926A patent/CN1128801C/zh not_active Ceased
- 1999-12-02 ID IDW00200101173A patent/ID29927A/id unknown
- 1999-12-02 PT PT03025536T patent/PT1386921E/pt unknown
- 1999-12-02 ES ES03025536T patent/ES2318081T3/es not_active Expired - Lifetime
- 1999-12-02 DE DE69915675T patent/DE69915675T4/de not_active Expired - Lifetime
- 1999-12-02 AT AT03025536T patent/ATE418547T1/de active
- 1999-12-02 IL IL14323299A patent/IL143232A0/xx unknown
- 1999-12-02 DK DK03025535.0T patent/DK1386917T3/da active
- 1999-12-02 CZ CZ20011962A patent/CZ295234B6/cs not_active IP Right Cessation
- 1999-12-02 TR TR2001/01567T patent/TR200101567T2/xx unknown
- 1999-12-02 EP EP03025537A patent/EP1386909A1/en not_active Withdrawn
- 1999-12-02 AT AT99963796T patent/ATE261970T1/de active
- 1999-12-02 SI SI9931026T patent/SI1386921T1/sl unknown
- 1999-12-02 KR KR1020017006907A patent/KR100742924B1/ko not_active Expired - Lifetime
- 1999-12-02 DE DE201112100004 patent/DE122011100004I1/de active Pending
- 1999-12-02 HK HK02101198.6A patent/HK1039933B/en unknown
- 1999-12-02 CA CA2351709A patent/CA2351709C/en not_active Expired - Lifetime
- 1999-12-02 DK DK99963796T patent/DK1135391T3/da active
- 1999-12-02 US US14/976,977 patent/USRE46276E1/en not_active Expired - Lifetime
- 1999-12-02 EP EP10183113A patent/EP2322513A3/en not_active Withdrawn
- 1999-12-02 EG EG154399A patent/EG24814A/xx active
- 1999-12-02 US US09/508,195 patent/US6525060B1/en not_active Ceased
- 1999-12-02 AT AT03025535T patent/ATE513816T1/de active
- 1999-12-02 EP EP03025536A patent/EP1386921B1/en not_active Expired - Lifetime
- 1999-12-02 KR KR1020077014185A patent/KR100764417B1/ko not_active Expired - Lifetime
- 1999-12-02 KR KR1020067015291A patent/KR100776484B1/ko not_active Expired - Lifetime
- 1999-12-02 EP EP03025535A patent/EP1386917B1/en not_active Expired - Lifetime
- 1999-12-02 KR KR1020067027016A patent/KR100822602B1/ko not_active Expired - Lifetime
- 1999-12-02 DE DE69915675A patent/DE69915675D1/de not_active Expired - Lifetime
- 1999-12-02 ES ES03025535T patent/ES2366902T3/es not_active Expired - Lifetime
- 1999-12-03 AR ARP990106165A patent/AR023920A1/es not_active Application Discontinuation
- 1999-12-27 SA SA99200848A patent/SA99200848B1/ar unknown
2001
- 2001-05-17 IL IL143232A patent/IL143232A/en active Protection Beyond IP Right Term
- 2001-05-18 ZA ZA200104094A patent/ZA200104094B/en unknown
- 2001-06-01 NO NO20012725A patent/NO319806B1/no active Protection Beyond IP Right Term
2002
- 2002-12-20 US US10/323,655 patent/US6974868B2/en not_active Expired - Lifetime
2005
- 2005-06-06 IL IL169013A patent/IL169013A/en not_active IP Right Cessation
- 2005-09-21 US US11/230,493 patent/US7250419B2/en not_active Expired - Lifetime
2006
- 2006-10-18 JP JP2006283455A patent/JP2007084551A/ja not_active Ceased
2007
- 2007-01-10 AR ARP070100095A patent/AR058967A2/es active IP Right Grant
- 2007-02-28 US US11/711,838 patent/US20070265282A1/en not_active Abandoned
- 2007-06-14 IL IL183969A patent/IL183969A/en not_active IP Right Cessation
- 2007-09-11 RU RU2007133926/04A patent/RU2007133926A/ru not_active Application Discontinuation
2008
- 2008-05-08 US US12/149,771 patent/US20080214812A1/en not_active Abandoned
- 2008-05-23 JP JP2008135275A patent/JP5043749B2/ja not_active Expired - Lifetime
2009
- 2009-02-26 CY CY20091100225T patent/CY1110501T1/el unknown
- 2009-04-06 IL IL198040A patent/IL198040A/en not_active IP Right Cessation
- 2009-08-11 AR ARP090103085A patent/AR072756A2/es active IP Right Grant
- 2009-11-18 US US12/591,395 patent/US20100069408A1/en not_active Abandoned
2010
- 2010-09-08 JP JP2010200486A patent/JP5415383B2/ja not_active Expired - Lifetime
- 2010-12-30 IL IL210398A patent/IL210398A0/en unknown
2011
- 2011-05-18 CY CY2011005C patent/CY2011005I2/el unknown
- 2011-05-23 FR FR11C0016C patent/FR11C0016I2/fr active Active
- 2011-05-23 NO NO2011007C patent/NO2011007I2/no unknown
- 2011-05-25 LT LTPA2011004C patent/LTPA2011004I1/lt unknown
- 2011-05-31 LU LU91819C patent/LU91819I2/fr unknown
- 2011-07-21 US US13/137,125 patent/US20120165348A1/en not_active Abandoned
- 2011-08-17 CY CY20111100786T patent/CY1111759T1/el unknown
2012
- 2012-03-19 US US13/423,848 patent/US20130072503A1/en not_active Abandoned
- 2012-05-25 RU RU2012121883/04A patent/RU2593201C2/ru active
- 2012-10-31 US US13/665,241 patent/US20130109702A1/en not_active Abandoned
2013
- 2013-09-05 HU HUS1300048C patent/HUS1300048I1/hu unknown
- 2013-10-31 US US14/068,942 patent/US20140296258A1/en not_active Abandoned
2014
- 2014-06-20 US US14/310,315 patent/US20150152111A1/en not_active Abandoned
2022
- 2022-03-23 NO NO2022007C patent/NO2022007I1/no unknown

Also Published As

Publication number	Publication date
US6525060B1 (en)	2003-02-25
IL210398A0 (en)	2011-03-31
US6974868B2 (en)	2005-12-13
NO2011007I2 (no)	2012-07-09
US20030144305A1 (en)	2003-07-31
SA99200848B1 (ar)	2006-11-04
US20130072503A1 (en)	2013-03-21
AR072756A2 (es)	2010-09-22
RU2593201C2 (ru)	2016-08-10
US20070265282A1 (en)	2007-11-15
RU2012121883A (ru)	2013-11-27
CN1334816A (zh)	2002-02-06
US20150152111A1 (en)	2015-06-04
CZ300373B6 (cs)	2009-05-06
ATE418547T1 (de)	2009-01-15
LU91819I2 (fr)	2011-08-01
HU228589B1 (en)	2013-04-29
DE69940171D1 (de)	2009-02-05
IL143232A (en)	2008-12-29
EP2322513A2 (en)	2011-05-18
TWI229674B (en)	2005-03-21
CY1110501T1 (el)	2015-04-29
US20100069408A1 (en)	2010-03-18
RU2007133926A (ru)	2009-03-20
US20060025590A1 (en)	2006-02-02
IL143232A0 (en)	2002-04-21
PL348724A1 (en)	2002-06-03
EG24814A (en)	2010-09-21
NZ511778A (en)	2003-10-31
ATE513816T1 (de)	2011-07-15
CY2011005I1 (el)	2014-04-09
KR20010081054A (ko)	2001-08-25
DK1386917T3 (da)	2011-08-29
DE122011100004I1 (de)	2011-09-08
IL183969A0 (en)	2009-02-11
CY1111759T1 (el)	2015-10-07
BRPI9915883B8 (pt)	2021-05-25
MY121867A (en)	2006-02-28
LTC1135391I2 (lt)	2022-04-11
TR200101567T2 (tr)	2001-12-21
KR20060091056A (ko)	2006-08-17
US7250419B2 (en)	2007-07-31
ID29927A (id)	2001-10-25
HK1039933B (en)	2004-10-08
EP1135391B1 (en)	2004-03-17
CA2351709A1 (en)	2000-06-15
EP1386921B1 (en)	2008-12-24
CY2011005I2 (el)	2014-04-09
JP2007084551A (ja)	2007-04-05
CZ300280B6 (cs)	2009-04-08
SK286007B6 (sk)	2008-01-07
NO20012725L (no)	2001-07-31
KR100776484B1 (ko)	2007-11-28
HUS1300048I1 (hu)	2017-03-28
EP1386917B1 (en)	2011-06-22
ATE261970T1 (de)	2004-04-15
EP2322513A3 (en)	2011-08-24
JP5415383B2 (ja)	2014-02-12
NO20012725D0 (no)	2001-06-01
SI1135391T1 (sl)	2004-08-31
SK7492001A3 (en)	2002-01-07
LTPA2011004I1 (lt)	2022-04-11
JP5043749B2 (ja)	2012-10-10
HK1061684A1 (en)	2004-09-30
JP2002531567A (ja)	2002-09-24
CZ20011962A3 (cs)	2001-11-14
JP4202607B2 (ja)	2008-12-24
CA2351709C (en)	2010-04-06
NO319806B1 (no)	2005-09-19
WO2000034283A1 (en)	2000-06-15
AU2016500A (en)	2000-06-26
HK1061246A1 (en)	2004-09-10
DK1386921T3 (da)	2009-03-23
IL198040A0 (en)	2009-12-24
FR11C0016I1 (sl)	2011-07-08
IL198040A (en)	2015-06-30
KR20070007971A (ko)	2007-01-16
AU766618B2 (en)	2003-10-23
ES2366902T3 (es)	2011-10-26
ZA200104094B (en)	2002-08-19
PT1386921E (pt)	2009-02-23
JP2008266345A (ja)	2008-11-06
DE69915675D1 (de)	2004-04-22
BR9915883A (pt)	2001-08-21
KR100742924B1 (ko)	2007-07-25
SI1386921T1 (sl)	2009-04-30
NO2011007I1 (no)	2011-06-06
EP1386921A1 (en)	2004-02-04
HUP0105081A2 (hu)	2002-05-29
DK1135391T3 (da)	2004-06-28
EP1135391A1 (en)	2001-09-26
KR100822602B1 (ko)	2008-04-16
HUP0105081A3 (en)	2004-11-29
PL201283B1 (pl)	2009-03-31
AR023920A1 (es)	2002-09-04
BRPI9915883B1 (pt)	2015-08-18
US20130109702A1 (en)	2013-05-02
KR100764417B1 (ko)	2007-10-05
EP1386909A1 (en)	2004-02-04
US20080214812A1 (en)	2008-09-04
PT1135391E (pt)	2004-07-30
AR058967A2 (es)	2008-03-05
ES2216623T3 (es)	2004-10-16
ES2318081T3 (es)	2009-05-01
EP1386917A1 (en)	2004-02-04
DE69915675T2 (de)	2005-02-17
US20120165348A1 (en)	2012-06-28
DE69915675T4 (de)	2012-08-30
IL169013A (en)	2015-10-29
NO2022007I1 (no)	2022-03-23
JP2011016831A (ja)	2011-01-27
CZ295234B6 (cs)	2005-06-15
KR20070086540A (ko)	2007-08-27
HK1039933A1 (en)	2002-05-17
CN1128801C (zh)	2003-11-26
USRE46276E1 (en)	2017-01-17
FR11C0016I2 (fr)	2012-03-16
RU2317990C2 (ru)	2008-02-27
US20140296258A1 (en)	2014-10-02
IL183969A (en)	2011-03-31

Publication	Publication Date	Title
SI1386917T1 (sl)	2011-09-30	Intermediati za pripravo nekaterih triazolopirimidinov kot P2T antagonistov
HUP0302345A3 (en)	2007-10-29	Novel triazolo pyrimidine compounds, their intermediates and process for their preparation
PL346237A1 (en)	2002-01-28	Sethod for the preparation of citalopram
GB2354240B (en)	2001-05-23	Method for the preparation of citalopram
GB2360281B (en)	2002-01-16	Method for the preparation of citalopram
GR3036917T3 (en)	2002-01-31	Process for the preparation of pyrimidine compounds
PL342430A1 (en)	2001-06-04	Novel compounds of triazolo[4,5-d]pyrimidine
IL146541A0 (en)	2002-07-25	Substituted imidazothiazoles as antidepressant agents
EG22530A (en)	2003-03-31	Preparation of substituted piperidin-4-ones
IL144516A0 (en)	2002-05-23	PROCESS FOR THE PREPARATION OF PYRAZOLO [4,3-d] PYRIMIDIN-7-ONE COMPOUNDS AND INTERMEDIATES THEREOF
PL350536A1 (en)	2002-12-16	Biphenyl derivatives as antagonists of the neurokinine-1 receptor
IL143784A (en)	2005-05-17	Intermediates for the preparation of eprosartan
IL145888A0 (en)	2002-07-25	Process for the preparation of substituted pyrimidines
HUP0200169A3 (en)	2002-11-28	Method for the preparation of citalopram
EG22775A (en)	2003-08-31	Process for the preparation of pyrazolo (f,5-d) pyrimidin 7 ones-3-pyridylsulphonyl compounds and intermediates thereof
HU228274B1 (en)	2013-02-28	Intermediates for the preparation of 2-imidazoline-5-ones
IL120560A0 (en)	1997-07-13	Process for the preparation of pyrimidinone compounds and intermediates produced thereby
SI1200414T1 (sl)	2005-10-31	Postopek za pripravo substituiranih pirimidinov
IL128844A (en)	2003-07-06	Process for the preparation of malononitrile
GB0018667D0 (en)	2000-09-13	Process for the preparation of pyrazolo [4,3-d] Pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof
ZA200005581B (en)	2002-04-11	Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof.
EG21680A (en)	2002-02-27	Process for the preparation of ampicillin
GB0107526D0 (en)	2001-05-16	Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-one compounds and intermediates thereof
ZA200106161B (en)	2003-01-27	Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof.
TW403100U (en)	2000-08-21	Structure improvement of the assembled flooring